Strategic Partnerships Novoheart has a history of high-profile collaborations with AstraZeneca, NHCS Singapore, Mayo Clinic, UCSD, and Curi Bio, indicating a strong partner network and a track record of integrating with pharma and research institutions. This points to sales opportunities in co-development, platform licensing, and contract research services with large biopharma, academic centers, and CROs seeking human-relevant cardiac models.

Scale potential With revenue reported in the high multi‑billion range and a focused, scalable mini‑heart platform, Novoheart could be positioned to upsell larger, multi‑year contracted studies, expanded model libraries (various heart conditions), and enterprise-level access to their MyHeart hvCoC platform for drug discovery programs requiring high-throughput, human-specific toxicity and efficacy testing.

Disease Modelling Focus The company specializes in human heart models including HLHS and HFpEF, offering disease-specific drug screening in human cells. This aligns well with opportunities in precision medicine, cardiovascular drug development, and safety testing, appealing to teams aiming to de-risk cardiotoxicity and tailor therapies to patient subgroups.

Global Academic Outreach Active collaborations with NHCS Singapore, UCSD, Mayo Clinic, and international press coverage demonstrate strong academic adoption. Sales approaches can target academic grants, sponsored research agreements, and technology transfer/licensing deals to expand the geographic footprint and build case studies.

Integrated Platform Integration with Curi Bio’s Pulse platform and the existing cloud-ready, ISO 9001–certified MyHeart platform highlight a valuable ecosystem. This creates cross-sell opportunities to customers already using complementary analytics and data platforms, enabling bundled solutions for data generation, analysis, and decision-making in drug discovery.